Five Women, Two Doses: Reading the First Psilocybin for Fibromyalgia Trial Like a Clinician

I'm building a literature review for a presentation at PainWeek 2026 in Las Vegas this September, and somewhere in the search results I came across a sentence I'd already seen repeated across the trade press: psilocybin-assisted therapy was "safe and well tolerated" in adults with fibromyalgia, with improvements across multiple symptom domains. Then I opened the actual paper.

The first clinical trial of psilocybin for fibromyalgia enrolled five people. Not fifty. Five. The headlines weren't false, but they were doing what headlines about psychedelics for chronic pain reliably do: reporting the conclusion without the denominator. For clinicians with fibromyalgia clients, who will hear about this study from a Facebook group long before they hear about it from a rheumatologist, the denominator is most of the story.

The study (Aday et al., Frontiers in Pain Research, March 2025) was an open-label pilot at the University of Michigan. Participants received two oral doses of psilocybin two weeks apart (15 mg, then 25 mg), embedded in a full therapy scaffold: two preparation sessions, two 8-hour dosing sessions with a therapist dyad present throughout, and four integration sessions.

The numbers worth knowing:

• 368 people inquired. Five completed. The funnel ran 368 inquiries → 265 pre-screened → 17 screened → 7 enrolled → 5 completers, all women, ages 37–63. The exclusion criteria did most of that narrowing, which tells you how far this protocol sits from a typical fibromyalgia caseload.
• Safety, the primary outcome, looked good at this scale. No serious adverse events. Transient blood pressure and heart rate elevations resolved by session's end; the most common related adverse event was mild-to-moderate headache (4 of 5), resolving within two days.
• Pain outcomes moved in the right direction. Mean pain severity dropped 2.3 points and pain interference 9.4 points, with very large effect sizes (Cohen's *d* of −2.1 and −1.8) and confidence intervals wide enough to drive a truck through, which is what five-person samples produce. Sleep disturbance improved similarly.
• The texture is more mixed than the summary. On global impression of change, one participant was "very much improved," two "much improved," and two only "minimally improved." Depression scores barely moved at all (*d* = 0.03). Whatever happened for these five women, it wasn't a uniform or across-the-board response.
• The trial stopped early, citing recruitment difficulty, generalizability concerns, and FDA guidance changes during data collection. The authors say plainly that the design "did not use a model of PAT that was clinically translational" and that results "likely do not generalize to typical clinical populations."

That's an honest paper. The honest reading: psilocybin for fibromyalgia cleared the lowest evidentiary bar (no safety disasters in five carefully selected patients) and generated effect-size estimates that justify a real trial. It established nothing about efficacy. Early evidence indicates a signal worth pursuing; it does not indicate a treatment.

Fibromyalgia is widely understood as a disorder of central sensitization: amplified pain processing in the central nervous system rather than ongoing tissue damage. That makes it a theoretically attractive target for a drug that acts on serotonin 2A receptors and appears, in preclinical work, to alter pain processing. Survey data points the same direction: in one survey of 64 people with fibromyalgia, most of those reporting any pain change with past psychedelic use described acute reduction. But self-selected survey respondents are hypothesis-generating, nothing more. The mechanism story is plausible. Plausible mechanisms fail in trials all the time; that's what the trials are for.

Two practical issues matter more for your practice than the effect sizes.

Medications. Fibromyalgia patients are very often on SSRIs, SNRIs (duloxetine and milnacipran are FDA-approved for the condition), tricyclics, or some combination. These are drugs with real pharmacological interactions with psilocybin, mostly in the direction of blunting its effects, with serotonergic safety questions still being worked out. This pilot initially excluded nearly all psychoactive medications and only later amended its protocol to allow SSRIs/SNRIs. Any client considering psilocybin in any setting is facing a tapering question, and tapering off the medication that's partially managing your pain condition is not a casual undertaking. That decision is a conversation with the prescriber — and it's exactly the kind of thing clients do unilaterally when nobody invites the conversation.

Population and access. Fibromyalgia patients are disproportionately women, and they arrive with a long history of being disbelieved, dismissed, and offered the next thing. They are precisely the population most vulnerable to being failed twice over: first by coverage that overpromises a five-person pilot into a breakthrough, then by an access landscape where the legal options (clinical trials with brutal exclusion criteria, or out-of-pocket state programs) were not built with chronic pain patients or their budgets in mind. Enthusiasm without access is a familiar prescription for this population. We should decline to write it again.

A workable shape for the conversation, in my experience: validate the interest (the curiosity is rational; the early data is genuinely interesting), name the evidence stage accurately ("one completed trial, five people, no control group; it tested safety, not whether it works"), surface the medication question explicitly, and keep the door open. A client who asks about psilocybin is telling you something about how their pain is doing and how their current treatment is going. That information is valuable even when the answer to "should I try mushrooms" is "the evidence isn't there yet, and here's what we'd need to think about together if you pursue it anyway." Harm reduction means engaging the question your client is actually asking.

The pipeline is real: a randomized fibromyalgia trial with brain biomarkers is underway, alongside studies in CRPS, phantom limb pain, and migraine and cluster headache. Controlled fibromyalgia data is likely within a few years. Until then, the clinically responsible position is the unexciting one. Psilocybin for fibromyalgia is a research question with a plausible mechanism, a clean five-person safety record, and no efficacy evidence yet. Your clients deserve that sentence, not the headline version.

An open-label University of Michigan pilot gave five women two psilocybin doses inside a full therapy scaffold. Safety, the primary outcome, looked good: no serious adverse events, mostly mild headache. Pain severity and interference dropped with very large but highly uncertain effect sizes. The trial stopped early, and the authors say results likely do not generalize.

Not established. The only completed trial enrolled five carefully selected patients, had no control group, and tested safety rather than efficacy. It generated effect-size estimates that justify a real trial but proved nothing about whether psilocybin works for fibromyalgia. Early evidence indicates a signal worth pursuing; controlled data is likely still a few years away.

This is a prescriber question, not a casual one. Fibromyalgia patients are often on SSRIs, SNRIs, or tricyclics, which interact with psilocybin, mostly by blunting its effects, with serotonergic safety still being worked out. Tapering off a medication that is partially managing pain is a significant decision that belongs with the prescribing clinician.

Validate the interest, then name the evidence stage accurately: one completed trial, five people, no control group, testing safety rather than efficacy. Raise the medication-tapering question explicitly, and keep the door open. A client asking about psilocybin is telling you something about how their pain and current treatment are going, which is valuable regardless.

Peter H. Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.

Working with clients exploring psychedelics for pain or mood? The Comprehensive KAP Assessment Bundle (2 CEs) covers the screening and assessment skills this work requires. And if a client has already had a psychedelic experience and you're not sure what to do next, the free guide What to Do After Your Client Uses Psychedelics is the place to start.